Earnings call transcript: HUTCHMED reports strong 2025 growth, stock dips
Entity Intersection Graph
No entity connections available yet for this article.
Original Source
Hutchison China MediTech Limited reported its 2025 full-year earnings, showcasing strong growth in its oncology business, driven by significant sales of its flagship product Fruquintinib. Despite the positive results, the company’s stock saw a slight pre-market dip of 1.39%, trading at $13.46. The current stock price of $13.85 suggests the company may be undervalued according to InvestingPro
Read full article at source